ClinicalTrials.gg
CompletedNCT07432997Updated Feb 25, 2026

Pharmacological Enhancement of Glymphatic Function in Humans

A Phase 1/2 interventional study of Dexmedetomidine and Dexmedetomidine and Midodrine in Alzheimer Disease, sponsored by Applied Cognition. Completed at 2 sites in United States. Open to participants aged 55 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Applied Cognition · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Dec 2023, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
55 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,141st of 1,609
31 · median 73
Started
2023
with 114 others
Phase 1/2
67 of 1,940
17 open now
Registered
1,877th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,141st largest by enrollment of the 1,609 interventional ones that give a count, is one of 115 that started in 2023, is one of 67 in phase 1/2, and was the 1,877th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

Alzheimer's disease is linked in part to the buildup of harmful proteins in the brain, including amyloid and tau. Most current treatments aim to remove these proteins directly. This study explores a different approach: helping the brain clear waste more effectively during sleep. The investigators will test whether certain medications can safely boost the brain's natural "cleaning system," known as the glymphatic system, in healthy older adults. Participants will receive controlled sleep treatments and blood tests to measure protein clearance. If successful, this strategy could support new therapies that work alongside existing Alzheimer's treatments.

Read the detailed description

Alzheimer's disease (AD) is driven in part by impaired clearance of aggregation-prone proteins, including amyloid-β (Aβ) and tau. Although current disease-modifying therapies primarily target direct protein sequestration, restoration of endogenous waste clearance represents a complementary and underexplored therapeutic strategy. Investigators propose a prospective, interventional study to evaluate whether pharmacologic modulation of sleep-associated glymphatic function enhances clearance of AD-relevant proteins in humans.

In this crossover study, healthy older adults will undergo controlled sleep interventions and receive either a single-agent therapy that suppresses central noradrenergic tone or a fixed-dose combination therapy designed to suppress central noradrenergic tone while stabilizing systemic vascular dynamics. The primary endpoint will be the change in plasma mass-balance indices of Aβ and tau clearance during a standardized overnight intervention.

Investigators hypothesize that coordinated modulation of central noradrenergic signaling and vascular stability will enhance sleep-associated, glymphatic-linked clearance of amyloid and tau. If confirmed, these findings would establish glymphatic modulation as a tractable and druggable systems pathway in humans and support further evaluation of clearance-augmenting strategies as complementary approaches to existing disease-modifying therapies for Alzheimer's disease and related proteinopathies.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • glymphatic
  • clearance
  • increase
  • drug
04

Who can participate

Ages eligible
55 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Potential participants must satisfy the following criteria to be enrolled in the study:

  1. In the opinion of the Principal Investigator, participants must be fluent in English and be able to understand the form approved by the Institutional Review Board (IRB). All participants must sign the study informed consent document indicating that they understand the purpose of procedures required for the study and are willing to participate in the study prior to any study procedures being performed.
  2. Participants may be men or women, age 55 - 65 years (inclusive). Enrollment will target equal number of men and women participants.
  3. Participants must have a score at least 26 for in-person assessment or 19 for over-the-phone assessment, unless waived by decision of the PI.
  4. Participants must have a GDS-15 score of 4 or less.
  5. Participants must provide an address and phone number where they can be accessible to the Study team for follow up.
  6. Participants must agree to wear the GF Monitor per the Study Phase under baseline and dexmedetomidine infusion and be willing to complete all other aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Potential participants who meet any of the following criteria will be excluded from participating in the study:

    1. Participants with a formal diagnosis of any sleep disorder (e.g., sleep apnea on PAP therapy, insomnia, restless leg syndrome, circadian rhythm sleep disorder, parasomnia).
    2. Participants with a history of significant neurological disease or history of epilepsy.
    3. Participants with cardiovascular disease or hypertension.
    4. Participants with diabetes.
    5. Participants with traumatic brain injury, or serious mental illness including bipolar disorder, schizophrenia, major depressive disorder or post-traumatic stress disorder.
    6. Participants who have taken in the past 30 days prescribed or over-the-counter (OTC) stimulants, sleeping medications, or psychiatric medications including antidepressants.
    7. Participants who consume more than 400 mg/day of caffeine. Participants will be required to not consume caffeine on the day-of the sleep study.
    8. Female Participants who consume more than 3 alcoholic drinks on any day or more than 7 drinks per week. Male participants who consume more than 4 alcoholic drinks on any day or more than 14 drinks per week.
    9. Participants who are enrolled in other research studies and are receiving an drug within 30 days of the planned start date for visit 1.
    10. Participants who have any condition that, in the opinion of the Principal Investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements.
    11. Participants who have a pre-planned surgery or medical procedure that would interfere with the conduct of the study.
    12. Participants with a serious infection requiring medical attention in the past 30 days.
    13. Any significant neurological impairment in the opinion of the Principal Investigator that would affect the GF Monitor data.
    14. Participants with a diagnosis of substance use-disorder in the past 2 years.
    15. Participants with urinary retention or requiring to void several times during the night
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Placebo comparator
    Dexmedetomidine Cross-Over Placebo

    Other: Placebo

  • Active comparator
    Dexmedetomidine Cross-Over Treatment

    Drug: Dexmedetomidine

  • Active comparator
    Dexmedetomidine & Midodrine Cross-Over Treatment

    Drug: Dexmedetomidine and Midodrine

  • Placebo comparator
    Dexmedetomidine & Midodrine Cross-Over Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in plasma Aβ42/Aβ40 ratio following dexmedetomidine treatment

    Measured with mass spectrometry

    Time frame: Pre/post 4-hour sleep period

  2. Mean change from baseline in plasma Aβ42/Aβ40 ratio following dexmedetomidine and midodrine treatment

    Measured with mass spectrometry

    Time frame: Pre/post 4-hour sleep period

  3. Mean change from baseline in plasma %p-tau217 following dexmedetomidine treatment

    Measured with mass spectroscopy

    Time frame: Pre/post 4-hour sleep period

  4. Mean change from baseline in plasma %p-tau217 following dexmedetomidine and midodrine treatment

    Measured with mass spectroscopy

    Time frame: Pre/post 4-hour sleep period

07

Study locations

2 sites
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Washington State University
    Spokane, Washington 99164, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Sep 2024, 9 months.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2026
First posted
Feb 25, 2026
StartActual
Dec 11, 2023
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 13, 2024
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07432997
Lead sponsor
Applied Cognition
Collaborators
Stanford University, Washington State University
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Dec 11, 2023
Primary completion
Sep 13, 2024
Completion
Sep 13, 2024
Last update
Feb 25, 2026

Study contacts

Paul Dagum, MD PhD
study director · Applied Cognition
Albert Cheung, MD
principal investigator · Stanford Hospital
Brieann C Satterfield, PhD
principal investigator · Washington State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midodrine

Start the discussion